Santaris Pharma, the developer of RNA-based therapies in San Diego and Denmark, said today it has expanded its alliance with Pfizer, which has agreed to pay the smaller company $14 million to continue developing its technology. Santaris is also eligible to receive milestone payments of as much as $600 million, and royalties on as many as 10 products Pfizer may develop over time using its RNA technology. The two companies started collaborating in January 2009, when Santaris struck the deal with Wyeth, which has since merged with Pfizer.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
